Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on OnKure Therapeutics. The associated price target was lowered to $34.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Robert Burns has given his Buy rating due to a combination of factors surrounding OnKure Therapeutics’ promising developments. The company’s lead candidate, OKI-219, is showing potential in its ongoing clinical trials. Despite the absence of objective responses so far, the drug has demonstrated favorable pharmacokinetics and a strong safety profile, which suggests it could be suitable for combination therapies.
Furthermore, OnKure is planning to release updated and initial results from various trials in early 2026, which could provide further insights into the drug’s efficacy. The company’s strategic focus on expanding OKI-219’s application beyond oncology into treating vascular malformations also adds to its potential growth. These elements, combined with the competitive landscape heating up, position OnKure Therapeutics as a compelling investment opportunity.
According to TipRanks, Burns is an analyst with an average return of -2.6% and a 41.25% success rate. Burns covers the Healthcare sector, focusing on stocks such as Exelixis, Replimune Group, and Cullinan Management.
In another report released on November 7, LifeSci Capital also maintained a Buy rating on the stock with a $21.00 price target.